We use cookies to ensure that we give you the best experience on our website. It will mean you have agreed with we would get cookies when you continue to see this website.
Our Regenerative Medicine team was formed in December, 2015. With consultation services for both business and developmental planning, and an operational division for implementation, the Regenerative Medicine team can provide guidance in developing an optimal solution.
Regenerative Medicine Specified by Government Order
Partial Revision of Order for Enforcement of Pharmaceutical Affairs Law, appended Table 1 (Re Article 2)
Human Cell/Tissue Products
Animal Cell/Tissue Products
Gene Therapy Products
Performance Profile
The major difficulties of developing Regenerative Medicines are that regulations and evaluation methods have not yet caught up to the advancements in the technologies. Remedy, is able to provide support to academia, healthcare institutions, and industry, through experience and accumulated data.
*Contents Of Consultation
We have formed a specialized team in the Regenerative Medicine business, capable of determining present investment value (NET Present Value: NPV) of projects based on various data. With thorough market valuation, we are capable of developing an effective strategy that provides an accurate investment value for our clients.
As a member of the Forum for Innovative Regenerative Medicine (FIRM), we are actively contributing to the advancement to Regenerative Medicine products
We are focused in developing specialists that will lead the industry, through the implementation of a training program